Featured

Neutrophils not so neutral in tumors after all

Neutrophils in tumors are known to play both pro- and anti-inflammatory roles, but how they affect responses to immunotherapy is incompletely understood. In work recently published in Immunity, Pei et al. evaluated neutrophils in the context of...

ILT2 identifies an unexploited pool of intratumoral CD8+ bystander T cells with TCR-independent cytotoxicity in renal cell carcinoma

Analyzing primary ccRCC samples, Laboureur et al. identified a subset of CD8+ILT2+PD-1- TILs that were terminally differentiated and expressed high baseline levels of granzyme B, perforin, and NKG2D, ...

Tumor-resident T cells and dendritic cells form an in situ archetype during immunotherapy response in melanoma

Pietro and Au et al. profiled melanoma lymph node metastases from untreated, ICB-resistant, and ICB-responsive patients using flow cytometry, mIHC, and single-cell transcriptomics to dissect tumor-res...

An ICAM1-targeting chimeric costimulatory receptor mimics the immune synapse and enhances tumor-specific T cell function

Min et al. developed an ICAM1-specific 4-1BB fusion protein. Engagement of this chimeric costimulatory receptor (ICCR) enhanced tumor cell conjugation and force-dependent immune synapse stability, tri...

Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance

Lei, Lu, and Xu et al. showed that cuproptosis induced immunogenic cell death, releasing DAMPs that drove DC maturation, DC-dependent cross-priming, and M1-like TAM and effector CD8+ T cell remodeling...

See all for this week

Previous Digests

taNKs on the frontline: CD39+ NK cells in the antitumor response

June 17, 2026

NK cell antitumor therapies are under development, but the functional states of tumoral NK cells remain poorly understood, limiting progress. Serger et al. profiled NK cells from non-small cell lung cancer (NSCLC) samples, identifying targetable subsets for immunotherapy. Their...

Unraveling the role of CCR1 in tumor myeloid cells

June 10, 2026

Pancreatic cancer (PDA) is a highly resistant and difficult-to-treat tumor type, often marked by extensive fibroinflammatory stroma and infiltration of immunosuppressive myeloid cells. These myeloid cells, including macrophages and granulocytes, have been noted to have high expression of CCR1...

AI reads between the sequences to decode TCR specificity

June 3, 2026

Predicting TCR recognition from sequence alone is challenging because TCRs with low sequence similarity may bind the same peptide–MHC (pMHC), whereas nearly identical TCR sequences may bind different pMHCs. Wang, Yeh, et al. developed a new approach to map...

See More Digests

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

Donate to support researchers

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ute Burkhardt

Ed Fritsch

Lauren Hitchings

Gaëlle Llambi

Maartje Wouters

Alex Najibi

Katherine J. Turner

Stan Wolf

Paula Hochman

Shishir Pant

Nathan Suek

Morgan Janes

More About Us

TESTIMONIALS

I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.

— Carl H. June, MD

Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).

Testimonials